Treatment of recurrent iridochoroiditis horses

 

(57) Abstract:

The invention relates to agriculture, in particular animal health, and can be used to treat horses, patients relapsing iridocyclitis. Treatment of recurrent iridochoroiditis is the purpose of the diet and the introduction subconjuctival medicines containing (wt. %):

Atropine sulfate 0,02 - 0,1

Dexamethasone 0,6-1,0

Gentamicin sulfate 0,6-1,0

Novocaine 0,3-0,5

Water Rest

moreover, the introduction is carried out 1 time a day at intervals of 4-5 days, additionally, instillaciei enter 0,8-1,0% solution mezatona based 1-2 drops 2-3 times a day for 14-21 days and per os 3-6 mg of acetylsalicylic acid per kg weight of the animal within 10-14 days. The method improves the efficiency of treatment up to 80-100%.

The invention relates to agriculture, in particular animal health, and can be used in animal husbandry for the treatment of horses, patients relapsing iridocyclitis.

There is a method of treatment of recurrent iridochoroiditis by diet and the introduction of subconjuctival dostatochno effective.

The technical effect of the invention is to increase the efficiency of the method by reducing relapses.

The technical result is achieved in a method of treatment of recurrent iridochoroiditis by diet and the introduction of subconjuctival atropine sulfate and water that subconjuctival impose additional dexamethasone gentamicin sulfate and novocaine, in the following ratio of components, wt.%:

Atropine sulfate 0,02-0,1

Dexamethasone 0,6-1,0

Gentamicin sulfate 0,6-1,0

Novocaine 0,3-0,5

Water the Rest

moreover, the introduction is carried out 1 time a day at intervals of 4-5 days, additionally, instillaciei enter 0,8-1,0% solution mezatona based 1-2 drops 2-3 times a day for 14-21 days and per os 3-6 mg of acetylsalicylic acid per kg weight of the animal within 10-14 days.

Acetylsalicylic acid, salicylic ester acetic acid (Reference “Medicines used in medical practice in the USSR". M.: Medicine, S. 38) - has antipyretic, analgesic and anti-inflammatory effect.

Atropine sulfate sulfate atropinelike ether d,1-tropovoy acid (S. 36) blocks m-x is no anti-inflammatory and antiallergic effect. Inhibits the release of ACTH.

Gentamicin sulfate is an antibiotic produced Mecromonospora purpurea or Echinospora (ibid, p. 85).

Novocaine (ibid, S. 251) - -Diethyl ether, para-aminobenzoic acid hydrochloride, used as a local anesthetic agent.

Mezaton (ibid, 212 S.) - 1-(meta-Oxyphenyl)-2-methylaminoethanol hydrochloride, used as adrenomimeticescoe tool expands the pupil and lowers intraocular pressure.

In the patent and scientific literature is not well-known technical solutions containing elements similar stated, i.e., the proposal meets the criterion of “novelty.”

We first established that the application of atropine sulfate, dexamethasone, gentamicin, novocaine in a certain ratio together with mezatona increases more than two times the effectiveness of a treatment for horses, patients relapsing iridocyclitis, i.e., the proposal meets the criterion of “inventive step”.

All ingredients are produced by the domestic industry, i.e., the sentence “industrially applicable”.

The invention is illustrated in the following examples.

Example 1. In the sulfate added 0.6 g of dexamethasone, 0.6 g of gentamicin sulfate, 0.3 g of novocaine and 98,48 g of water, i.e., have the structure 1 in the following ratio, wt.%:

Atropine sulfate 0,02

Dexamethasone 0,6

Gentamicin sulfate 0,6

Novocaine 0,3

Water the Rest

To 0.1 g of atropine sulfate add 1.0 g of dexamethasone, 1.0 g of gentamicin sulfate, 0.5 g of novocaine and of 97.4 g of water, i.e., get part 2 in the following ratio, wt.%:

Atropine sulfate is 0.1

Dexamethasone 1,0

Gentamicin sulfate 1,0

Novocaine 0,5

Water the Rest

To 0.05 g of atropine sulfate add 0.8 g of dexamethasone, 0.8 g of gentamicin sulfate, 0.4 g of novocaine and 97,95 g of water, i.e., the receiving part 3 in the following ratio, wt.%:

Atropine sulfate 0.05

Dexamethasone 1,0

Gentamicin sulfate 1,0

Novocaine 0,5

Water the Rest

Pick four groups of horses, patients relapsing iridocyclitis, on the principle of analogues for 10 animals in each group. The first group in the eyes of the animals subconjuctival have introduced the structure 1, the second group - part 2, the third group - part 3. The fourth group served to the injection of compounds 1-3 was performed 1 time per day at intervals of 4 days within 14 days against the backdrop of diets. 0.8% solution mezatona was introduced by instillaciei (dropped in into the conjunctival SAC) 1 drop 2 times a day for 14 days. Animals were also given per os 6 mg of acetylsalicylic acid per kg weight of the animal within 14 days. As a result, in the first three groups completely disappeared acute clinical signs of disease (keratitis and iridocyclitis) 27 animals (90%), recurrence was found in only three animals (10%). In a fourth control group acute clinical signs preserved in all animals (0%), and relapse occurred in all horses (100%).

Example 2. Use the compounds 1-3, obtained in accordance with example 1. Pick four groups of horses, patients relapsing iridocyclitis, on the principle of analogues for 10 animals in each group. The first group in the eyes of the animals subconjuctival have introduced the structure 1, the second group - part 2, the third group - part 3. The fourth group served as control animals were injected as in the known method, a 0.1% aqueous solution of atropine sulfate. Subconjuctival injection of compounds 1-3 was performed 1 time per day with an interval of 5 days within 21 days against the backdrop of diets. 1,0% solution mezatona was introduced by instillaciei 2 drops 3 times a day for 21 days. Diet was, the per kg weight of the animal within 10 days. The result: in the first third groups completely disappeared acute clinical signs of disease (keratitis and iridocyclitis) in 28 animals (93%), recurrence was found in only two animals (7%) for the whole observation period (100 days). In a fourth control group acute clinical signs disappeared, only one horse (10%), and relapse occurred in all animals (100%).

Example 3. Use the compounds 1-3, obtained in accordance with example 1. Pick four groups of horses, patients relapsing iridocyclitis, on the principle of analogues for 10 animals in each group. The first group in the eyes of the animals subconjuctival have introduced the structure 1, the second group - part 2, the third group - part 3. The fourth group served as control animals were injected as in the known method, a 0.1% aqueous solution of atropine sulfate. Subconjuctival injection of compounds 1-3 was performed 1 time per day every 5 days for 18 days on the background diet. 0.9% solution mezatona was introduced by instillaciei 2 drops 3 times a day for 18 days. The diet consisted, as in the known method, the withdrawal from the diet of oats. Animals were also given per os 3 mg of acetylsalicylic acid per kg weight of the animal within 10 days. The result: in the first Tr is (97%), relapse was not found neither in one animal (0%) for the whole observation period (100 days). In a fourth control group acute clinical signs disappeared, only one horse (10%), and relapse occurred in all animals (100%).

Thus, the proposed method for the treatment of recurrent iridochoroiditis allows 93-100% reduction in the recurrence of the disease, and 80-100% increase in the recovery of animals from acute clinical signs of recurrent iridochoroiditis.

Treatment of recurrent iridochoroiditis by subconjuctival introduction on the background diet medicines containing atropine sulfate and water, characterized in that the medicinal product further comprises dexamethasone gentamicin sulfate and novocaine in the following ratio, wt.%:

Atropine sulfate 0,02-0,1

Dexamethasone 0,6-1,0

Gentamicin sulfate 0,6-1,0

Novocaine 0,3-0,5

Water the Rest

moreover, the introduction is carried out 1 time a day at intervals of 4-5 days, additionally, the instillation enter 0,8-1,0% solution mezatona based 1-2 drops 2-3 times a day for 14-21 days and per os 3-6 mg acetylsalicylic acid, and n is

 

Same patents:

The invention relates to the field of medicine and relates to a composition for topical application, reducing intraocular pressure, comprising the antagonist of angiotensin II, boric acid and ethylenediaminetetraacetic acid
The invention relates to medicine, in particular to ophthalmology, and can be used in the treatment pseudophoenix diseases of the orbit

The invention relates to medicine, in particular to ophthalmology, and can be used as ophthalmic medicines for the treatment of diseases and injuries of the cornea
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of patients with diabetic retinopathy
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of postinflammatory bullous keratopathy

The invention relates to medicine, namely to ophthalmology, and for the treatment of edematous maculopathy
The invention relates to medicine, namely to ophthalmology, and for the prevention of postoperative complications antiglaucomatous surgery
The invention relates to medicine, namely to ophthalmology, and for the treatment of endocrine ophthalmopathy

The invention relates to medicine, to the agent for the prevention or treatment of diseases associated with excessive proliferation of the epithelial pigment cells of the retina, such as proliferative vitreoretinopathy, and includes as the active ingredient N-(3,4-dimethoxycinnamoyl) Anthranilic acid of formula I or its pharmaceutically acceptable salt
The invention relates to medicine, namely to ophthalmology, and for the treatment of degenerative diseases of the retina
The invention relates to veterinary

The invention relates to the field of veterinary medicine

The invention relates to the field of dentistry

The invention relates to medicine, namely to experimental pharmacology and cardiology

The invention relates to medicine, specifically to antientropy using antisense oligonucleotides

The invention relates to the field of clinical medicine - Phthisiology and can be used in the treatment of patients with caseous pneumonia to reduce the severity of the intoxication syndrome, normalization of blood system, withdrawal side effects from anti-TB therapy

The invention relates to medicine, specifically to the means that have antibacterial properties, and can be used to treat upper and lower respiratory tract, urinary tract, skin infections, soft tissue
The invention relates to medicine, namely to addiction
Up!